CR20170598A - Compuestos inhibidores de señalización de la trayectoria notch - Google Patents

Compuestos inhibidores de señalización de la trayectoria notch

Info

Publication number
CR20170598A
CR20170598A CR20170598A CR20170598A CR20170598A CR 20170598 A CR20170598 A CR 20170598A CR 20170598 A CR20170598 A CR 20170598A CR 20170598 A CR20170598 A CR 20170598A CR 20170598 A CR20170598 A CR 20170598A
Authority
CR
Costa Rica
Prior art keywords
notch
traffic signal
inhibiting compounds
signal inhibiting
loss
Prior art date
Application number
CR20170598A
Other languages
English (en)
Inventor
Aaron D Wrobleski
Julia Marie Clay
Philip Arthur Hipskind
Bharvin Kumar Patel
John C Gill
Es Helmuth Hendrikus Gerardus Van
Albert Edge
Gaiying Zhao
Original Assignee
Lilly Co Eli
Audion Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Audion Therapeutics filed Critical Lilly Co Eli
Publication of CR20170598A publication Critical patent/CR20170598A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona compuestos, o una sal farmacéuticamente aceptable de estos, y una composición farmacéutica que contiene dichos compuestos o una sal farmacéuticamente aceptable de esta, útil como un inhibidor de la señalización de la vía Notch para el tratamiento de los cánceres nombrados, pérdida de audición neurosensorial causada por la pérdida de células ciliadas auditivas, e inducción de la generación de células ciliadas auditivas
CR20170598A 2015-07-07 2016-07-01 Compuestos inhibidores de señalización de la trayectoria notch CR20170598A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562189393P 2015-07-07 2015-07-07
PCT/US2016/040612 WO2017007702A1 (en) 2015-07-07 2016-07-01 Notch pathway signaling inhibitor compounds

Publications (1)

Publication Number Publication Date
CR20170598A true CR20170598A (es) 2018-03-20

Family

ID=56507825

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20220368A CR20220368A (es) 2015-07-07 2016-07-01 Compuestos inhibidores de señalización de la trayectoria notch (divisional exp. n°2017-0598)
CR20170598A CR20170598A (es) 2015-07-07 2016-07-01 Compuestos inhibidores de señalización de la trayectoria notch

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR20220368A CR20220368A (es) 2015-07-07 2016-07-01 Compuestos inhibidores de señalización de la trayectoria notch (divisional exp. n°2017-0598)

Country Status (42)

Country Link
US (1) US10450317B2 (es)
EP (1) EP3319967B1 (es)
JP (1) JP6571214B2 (es)
KR (1) KR102078946B1 (es)
CN (1) CN107849054B (es)
AR (1) AR105080A1 (es)
AU (1) AU2016289822B2 (es)
CA (1) CA2987431C (es)
CL (1) CL2018000007A1 (es)
CO (1) CO2018000224A2 (es)
CR (2) CR20220368A (es)
CY (1) CY1122024T1 (es)
DK (1) DK3319967T3 (es)
DO (1) DOP2018000005A (es)
EA (1) EA032634B1 (es)
EC (1) ECSP18000042A (es)
ES (1) ES2735139T3 (es)
HK (1) HK1247187B (es)
HR (1) HRP20191175T1 (es)
HU (1) HUE044666T2 (es)
IL (1) IL255726B (es)
JO (1) JO3491B1 (es)
LT (1) LT3319967T (es)
MA (1) MA42399B1 (es)
MD (1) MD3319967T2 (es)
ME (1) ME03495B (es)
MX (1) MX2017016555A (es)
MY (1) MY197519A (es)
NZ (1) NZ737322A (es)
PE (1) PE20180412A1 (es)
PH (1) PH12018500047B1 (es)
PL (1) PL3319967T3 (es)
PT (1) PT3319967T (es)
RS (1) RS59115B1 (es)
SI (1) SI3319967T1 (es)
SV (1) SV2017005597A (es)
TN (1) TN2017000495A1 (es)
TR (1) TR201908683T4 (es)
TW (1) TWI625332B (es)
UA (1) UA120539C2 (es)
WO (1) WO2017007702A1 (es)
ZA (1) ZA201707858B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3491B1 (ar) 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
KR20190024983A (ko) 2016-06-29 2019-03-08 오토노미, 인코포레이티드 트리글리세라이드 귀 제제 및 이의 용도
US11253193B2 (en) * 2016-11-08 2022-02-22 Cochlear Limited Utilization of vocal acoustic biomarkers for assistive listening device utilization
AU2017376109A1 (en) 2016-12-16 2019-07-11 Pipeline Therapeutics, Inc. Methods of treating cochlear synaptopathy
JP2020511486A (ja) * 2017-03-24 2020-04-16 ノバルティス アーゲー イソオキサゾールカルボキサミド化合物及びその使用
US11117932B2 (en) * 2018-07-20 2021-09-14 The Hong Kong Polytechnic University Peptides for specific inhibition of Jag 1-Notch 1 pathway
KR20210066848A (ko) * 2018-09-21 2021-06-07 노파르티스 아게 이속사졸 카르복사미드 화합물 및 이의 용도
EP3860562A1 (en) 2018-10-02 2021-08-11 Frequency Therapeutics, Inc. Pharmaceutical compositions comprising otic therapeutic agents and related methods
US20220008433A1 (en) * 2018-11-30 2022-01-13 Massachusetts Eye And Ear Infirmary Inhibition of Lysine Demethylase 1 (Lsd1) Induces Differentiation of Hair Cells
AU2020271067A1 (en) 2019-04-08 2021-11-25 Frequency Therapeutics, Inc. Combination of CHIR99021 and valproic acid for treating hearing loss
WO2021150672A2 (en) * 2020-01-22 2021-07-29 Beth Israel Deaconess Medical Center, Inc. Biomarkers for placenta accreta spectrum (pas) disorders
WO2023200017A1 (en) * 2022-04-11 2023-10-19 Prism BioLab Co., Ltd. Novel seven-membered ring-fused compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673634B2 (en) 2003-11-13 2014-03-18 Massachusetts Eye & Ear Infirmary Method for the treatment of hearing loss
ES2398531T3 (es) 2006-03-27 2013-03-20 F. Hoffmann-La Roche Ag Derivados de malonamida como inhibidores de gamma secretasa
AU2009212135B2 (en) 2008-02-07 2014-08-21 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh-1 expression
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
JP5809061B2 (ja) 2008-11-24 2015-11-10 マサチューセッツ・アイ・アンド・イア・インファーマリー 有毛細胞を産生するための経路
WO2012047706A2 (en) 2010-10-06 2012-04-12 Massachusetts Eye & Ear Infirmary Methods for promotiing reinnervation of auditory hair cells
JO3148B1 (ar) * 2011-07-27 2017-09-20 Lilly Co Eli مركب مثبط لإشارات مسار notch
US8716229B2 (en) 2011-11-09 2014-05-06 Massachusetts Eye & Ear Infirmary Osteoprotegerin in neuroprotection
US20150209367A1 (en) * 2012-09-07 2015-07-30 Massachusetts Eye & Ear Infirmary Treating Hearing Loss
US20140134136A1 (en) 2012-11-02 2014-05-15 Massachusetts Eye And Ear Infirmary Compositions and methods for auditory therapy
JO3491B1 (ar) 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
AU2017376109A1 (en) * 2016-12-16 2019-07-11 Pipeline Therapeutics, Inc. Methods of treating cochlear synaptopathy

Also Published As

Publication number Publication date
HRP20191175T1 (hr) 2019-10-04
PH12018500047A1 (en) 2018-07-09
EP3319967B1 (en) 2019-05-22
TW201712016A (zh) 2017-04-01
KR102078946B1 (ko) 2020-02-19
MD3319967T2 (ro) 2019-11-30
JO3491B1 (ar) 2020-07-05
CL2018000007A1 (es) 2018-06-29
AR105080A1 (es) 2017-09-06
PT3319967T (pt) 2019-07-29
NZ737322A (en) 2019-05-31
ME03495B (me) 2020-01-20
HUE044666T2 (hu) 2019-11-28
CA2987431A1 (en) 2017-01-12
IL255726A (en) 2018-01-31
TR201908683T4 (tr) 2019-07-22
US20180148456A1 (en) 2018-05-31
CN107849054A (zh) 2018-03-27
EP3319967A1 (en) 2018-05-16
DK3319967T3 (da) 2019-07-22
CN107849054B (zh) 2020-04-28
HK1247187B (zh) 2020-01-10
EA201792478A1 (ru) 2018-06-29
PH12018500047B1 (en) 2018-07-09
CA2987431C (en) 2019-11-26
RS59115B1 (sr) 2019-09-30
MY197519A (en) 2023-06-19
MA42399B1 (fr) 2019-08-30
UA120539C2 (uk) 2019-12-26
LT3319967T (lt) 2019-08-12
IL255726B (en) 2020-10-29
ZA201707858B (en) 2020-01-29
EA032634B1 (ru) 2019-06-28
ES2735139T3 (es) 2019-12-16
CY1122024T1 (el) 2020-10-14
PL3319967T3 (pl) 2019-10-31
SI3319967T1 (sl) 2019-08-30
JP2018520157A (ja) 2018-07-26
CO2018000224A2 (es) 2018-04-10
ECSP18000042A (es) 2018-03-31
MX2017016555A (es) 2018-11-09
TWI625332B (zh) 2018-06-01
CR20220368A (es) 2022-08-23
US10450317B2 (en) 2019-10-22
AU2016289822A1 (en) 2017-11-30
AU2016289822B2 (en) 2018-07-26
MA42399A (fr) 2018-05-16
TN2017000495A1 (en) 2019-04-12
DOP2018000005A (es) 2018-10-31
KR20180011314A (ko) 2018-01-31
PE20180412A1 (es) 2018-03-01
WO2017007702A1 (en) 2017-01-12
SV2017005597A (es) 2019-04-04
JP6571214B2 (ja) 2019-09-04

Similar Documents

Publication Publication Date Title
ECSP18000042A (es) Compuestos inhibidores de la señalización de la vía de notch
CO2019007839A2 (es) Composiciones y métodos para inhibir la acción de la arginasa
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
SV2016005180A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
PE20151594A1 (es) Inhibidores de indolamina 2-3 dioxigenasa
ECSP17054980A (es) Inhibidores selectivos de bace1
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
UY34062A (es) ?compuestos heterocíclicos fusionados moduladores de canal ionico para el tratamiento de enfermedades que responden al bloqueo de canal de sodio?.
EA201591509A1 (ru) Ингибиторы cdc7
UY36630A (es) Moduladores tricíclicos de la señalización por tnf
CR20140508A (es) Moduladores de la ruta del complemento y usos de los mismos
UY36629A (es) Indazolonas como moduladores de la señalización de tnf
CL2018001067A1 (es) Compuesto piranodipiridínico.
CU24434B1 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
UY36628A (es) Indazolonas como moduladores de la señalización de tnf
CL2017000662A1 (es) Inhibidores de la histona desmetilasa.
CL2018000727A1 (es) Formulaciones de olanzapina de liberación sostenida
CL2015003037A1 (es) Derivados de triazina
AR109209A1 (es) Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas
EA201791596A1 (ru) Пиразоловые соединения
CU20140127A7 (es) Moduladores de la ruta del complemento y usos de los mismos
CO7141426A2 (es) Moduladores de la ruta del complemento y usos de los mismos
CR20160175A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa